New monoclonal antibodies for non-Hodgkin's lymphoma

Annals of Oncology

Volumn 19, Issue SUPPL. 4, 2008, Pages

  Leonard, J P ^a   Martin, P ^a   Ruan, J ^a   Elstrom, R ^a   Barrientos, J ^a   Coleman, M ^a   Furman, R R ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AME 133; ATUMUMAB; B7 ANTIGEN; CD20 ANTIBODY; CD22 ANTIBODY; CD22 ANTIGEN; CD40 ANTIBODY; CD40 ANTIGEN; CD80 ANTIBODY; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPRATUZUMAB; FLUDARABINE; GA 101; GALIXIMAB; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; OFATUMUMAB; PREDNISONE; RITUXIMAB; SGN 40; UNCLASSIFIED DRUG; VELTUZUMAB; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG TARGETING; FOLLICULAR LYMPHOMA; HUMAN; INJECTION SITE REACTION; LARGE CELL LYMPHOMA; LOW DRUG DOSE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; LYMPHOMA, NON-HODGKIN; TREATMENT OUTCOME;

EID: 48149083180     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn199     Document Type: Article

References (15)

1. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
2. Feugier P, Van Hoof A, Sebban C et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117-4126.
3. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004; 103: 2738-2743.
4. Teeling JL, French RR, Cragg MS et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004; 104: 1793-1800.
5. Hagenbeek A, Plesner T, Johnson P et al. HuMax-CD20, a novel fully human anti-CD20 monoclonal antibody: Results of a phase I/II trial in relapsed or refractory follicular non-Hodgkins's lymphoma. ASH Annual Meeting Abstracts 2005; 106: 4760.
6. Stein R, Qu Z, Chen S et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 2004; 10: 2868-2878.
7. Morschhauser F, Leonard JP, Coiffier B et al. Phase I/II results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20), in NHL. ASCO Meeting Abstracts 2006; 24: 7530.
8. Shinkawa T, Nakamura K, Yamane N. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278: 3466-3473.
9. Umana P, Moessner E, Bruenker P et al. Novel 3rd generation humanized type II CD20 antibody with glycoengineered Fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction. ASH Annual Meeting Abstracts 2006; 108: 229.
10. Weiner GJ, Bowles JA, Link BK, Campbell MA, Wooldridge JE, Breitmeyer JB. Anti-CD20 monoclonal antibody (mAb) with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab (R). ASH Annual Meeting Abstracts 2005; 106: 348.
11. Leonard JP, Coleman M, Ketas JC et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 2003; 21: 3051-3059.
12. Leonard JP, Coleman M, Ketas J et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 5044-5051.
13. Advani R, Forero-Torres A, Furman RR et al. SGN-40 (anti-huCD40 mAb) monotherapy induces durable objective responses in patients with relapsed aggressive non-Hodgkin's lymphoma: Evidence of antitumor activity from a phase I study. ASH Annual Meeting Abstracts 2006; 108: 695.
14. Czuczman MS, Thall A, Witzig TE et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 2005; 23: 4390-4398.
15. Friedberg JW, Leonard JP, Younes A et al. Updated results from a phase II study of galiximab (anti-CD80) in combination with rituximab for relapsed or refractory, follicular NHL. ASH Annual Meeting Abstracts 2005; 106: 2435.